CP 724714
Alternative Names: CP-724,714Latest Information Update: 02 Oct 2021
At a glance
- Originator OSI Pharmaceuticals; Pfizer
- Developer Pfizer
- Class Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Dec 2004 A clinical study has been added to the adverse events and Cancer pharmacodynamics sections
- 07 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the adverse events and pharmacokinetics sections
- 19 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section ,